Treeline Biosciences, a clinical-stage oncology biotech, disclosed a $200 million extension to its Series A round, bringing total funding to $1.1 billion. Alongside the financing, the company revealed its first three clinical candidates targeting various cancer pathways, including a broad KRAS mutant inhibitor and a protein degrader. Treeline’s strategy departs from milestone-driven financing, opting for a diversified, well-capitalized pipeline with investor support for multiple programs. This approach is designed to advance several programs concurrently and build a team for repeated innovation.